AbCellera Partners with Vertex to Develop Multispecific T-Cell Engagers for Autoimmune Diseases
Deals·2 articles across 2 outlets·◆ Primary source
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
AbCellera has announced a collaboration with Vertex to discover multispecific T-cell engagers aimed at treating autoimmune diseases and other conditions. This partnership adds to Vertex's efforts to diversify its portfolio, which has been heavily reliant on cystic fibrosis medicines.
The collaboration reflects a growing trend of partnerships focused on innovative T-cell engagers, positioning both companies to advance their research and development in this area.
AbCelleraVertex
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions”
SEC Filing — AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
AnalysisInterprets it
“The deal adds to a growing streak of partnerships involving new types of T cell engagers and gives Vertex another chance to broaden a business still reliant on cystic fibrosis medicines.”
biopharma dive — AbCellera, Vertex partner on next-gen T-cell engagers